Patent ID: 9481721
Filing Date: 2016-11-01
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A pharmaceutical formulation comprising an insulin derivative selected from the group consisting of A14E, B16H, B25H, B29K((N ε eicosanedioyl-γGlu-[2-(2-{2-[2-(2-aminoethoxy)-ethoxy]acetylamino}ethoxy)ethoxy]acetyl)), desB30 human insulin; A14E, B16H, B25H, B29K-(N ε hexadecandioyl-γGlu), desB30 human insulin; A14E, B16H, B25H, B29K(N ε eicosanedioyl-γGlu), desB30 human insulin; and A14E, B25H, desB27, B29K(N ε -(octadecandioyl-γGlu), desB30 human insulin, and from about 1 to about 2% (weight/weight) of glycerol, from about 16 to about 35 mM of phenol, from about 16 to about 35 mM of m-cresol, from about 3.5 to about 5.5 mole of zinc ions per six mole of said insulin derivative and not more than about 75 mM of sodium chloride.